Highlights:

  • IDT Australia (ASX:IDT) shares were trading at AUD 0.046, up 12.20% on 20 August 2026, while remaining down 34.29% over the past year.
  • Revenue across three core verticals increased 16.5% YoY to AUD 16.8 million in FY2026.
  • EBITDA loss narrowed 85% YoY to AUD 0.9 million compared with an EBITDA loss of AUD 6.3 million in FY2025.
  • The company is forecasting positive EBITDA for FY2027 and has set a target of AUD 50 million Revenue by FY2029.
  • IDT Australia plans AUD 7 million Capital Investment across a new sterile Manufacturing line and solid oral manufacturing upgrades.

IDT Australia Limited (ASX:IDT) has reported its FY2026 results, highlighting revenue growth across its manufacturing divisions, a reduction in EBITDA losses, and a strategic focus on improving profitability while expanding manufacturing capabilities.

IDT Australia shares were trading at AUD 0.046, up 12.20% during the morning Trading session on 20 August 2026, while remaining down 34.29% over the past year. The company’s FY2026 presentation outlined progress across its Active Pharmaceutical Ingredient (API), Solid Oral Manufacturing, and Sterile Manufacturing divisions, along with its outlook for FY2027 and longer-term revenue targets.

IDT Australia operates as a specialist Contract Development and Manufacturing Organisation (CDMO), providing manufacturing services for pharmaceutical and biotechnology companies across complex small-molecule API, sterile manufacturing, and non-sterile manufacturing.

Revenue Growth Across Three Manufacturing Verticals

IDT Australia reported revenue of AUD 16.8 million across its three core verticals in FY2026, representing a 16.5% increase compared with AUD 14.4 million in FY2025.

Including distribution revenue, total revenue reached AUD 20.4 million compared with AUD 19.2 million in FY2025.

The company recorded revenue growth across two of its three manufacturing areas. API Manufacturing revenue increased 29.4% to AUD 5.4 million, while Solid Oral Manufacturing revenue increased 51.7% to AUD 5.5 million.

Sterile Manufacturing revenue declined 10.8% to AUD 5.9 million, with the company attributing the movement to contract timing.

EBITDA Loss Narrows as Company Focuses on Profitability

IDT Australia reported an EBITDA loss of AUD 0.9 million in FY2026, representing an 85% reduction compared with the AUD 6.3 million EBITDA loss recorded in FY2025.

The company said the result reflected improved Operating Leverage alongside revenue growth and cost savings of approximately AUD 2.5 million during FY2026.

IDT Australia reported a strategic reset focused on prioritising profit over revenue growth, strengthening financial discipline, and increasing focus on high-value repeat clients.

API and Solid Oral Divisions Record Revenue Increases

The company’s API Manufacturing division recorded revenue growth of 29% to AUD 5.4 million during FY2026. IDT Australia said the division remains a foundation Business supporting its broader manufacturing platform.

The API division focuses on small-molecule and complex high-potency chemistry, with the company highlighting potential flow-on work opportunities across its other manufacturing services.

Solid Oral Manufacturing revenue increased 52% to AUD 5.5 million in FY2026. The company said the division benefited from opportunities in radiopharmaceuticals, medicinal cannabis, and psychedelic-related clients, with capabilities covering tablets, capsules, and liquid manufacturing.

Sterile Manufacturing Expansion and Capital Investment Plans

IDT Australia reported Sterile Manufacturing revenue of AUD 5.9 million in FY2026, down 11% compared with the previous year. The company said the decline reflected the timing of contracts.

The company identified sterile manufacturing as a growth area and highlighted its Sanofi “Preferred Vendor” status as part of its capabilities in this segment.

IDT Australia plans to invest AUD 7 million during FY2027-FY2028 to expand manufacturing capacity. The investment includes a new sterile manufacturing line using isolator technology and upgrades to solid oral manufacturing capabilities.

The sterile manufacturing investment is expected to support commercial-scale fill-finish capabilities, while the solid oral upgrade includes investment in tablet pressing, coating, solids handling, and bottle-line capabilities.

The company said the capital investment is fully funded through an existing Debt Facility and access to government grant programs.

FY2027 Outlook and FY2029 Revenue Target

IDT Australia is forecasting double-digit revenue growth and positive EBITDA for FY2027.

The company has set a target of AUD 50 million annualised revenue by FY2029, supported by customer expansion, strategic account management, pipeline growth, and new customer Acquisition initiatives across the US, Europe, and Asia-Pacific regions.

The company said its near and medium-term focus includes increasing repeat and follow-on work with existing strategic clients, expanding capabilities in selected high-value markets, and building customer acquisition opportunities within biotechnology clusters.

Investor Takeaway

IDT Australia’s FY2026 results show a period of revenue growth across its manufacturing divisions and a reduction in EBITDA losses compared with FY2025. The company is now focused on achieving positive EBITDA in FY2027, expanding manufacturing capabilities through AUD 7 million of planned investment, and progressing towards its AUD 50 million FY2029 revenue target.

Investors may continue to monitor execution of the company’s growth initiatives, delivery of its capital investment program, customer expansion activities, and progress towards its stated financial objectives.